Cargando…

Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines

OBJECTIVES: Many radiologists and clinicians still consider multiple myeloma (MM) and monoclonal gammopathies (MG) a contraindication for using iodine-based contrast media. The ESUR Contrast Media Safety Committee performed a systematic review of the incidence of post-contrast acute kidney injury (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Stacul, Fulvio, Bertolotto, Michele, Thomsen, Henrik S., Pozzato, Gabriele, Ugolini, Donatella, Bellin, Marie-France, Bongartz, Georg, Clement, Olivier, Heinz-Peer, Gertraud, van der Molen, Aart, Reimer, Peter, Webb, Judith A. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740198/
https://www.ncbi.nlm.nih.gov/pubmed/28856420
http://dx.doi.org/10.1007/s00330-017-5023-5
_version_ 1783288003586686976
author Stacul, Fulvio
Bertolotto, Michele
Thomsen, Henrik S.
Pozzato, Gabriele
Ugolini, Donatella
Bellin, Marie-France
Bongartz, Georg
Clement, Olivier
Heinz-Peer, Gertraud
van der Molen, Aart
Reimer, Peter
Webb, Judith A. W.
author_facet Stacul, Fulvio
Bertolotto, Michele
Thomsen, Henrik S.
Pozzato, Gabriele
Ugolini, Donatella
Bellin, Marie-France
Bongartz, Georg
Clement, Olivier
Heinz-Peer, Gertraud
van der Molen, Aart
Reimer, Peter
Webb, Judith A. W.
author_sort Stacul, Fulvio
collection PubMed
description OBJECTIVES: Many radiologists and clinicians still consider multiple myeloma (MM) and monoclonal gammopathies (MG) a contraindication for using iodine-based contrast media. The ESUR Contrast Media Safety Committee performed a systematic review of the incidence of post-contrast acute kidney injury (PC-AKI) in these patients. METHODS: A systematic search in Medline and Scopus databases was performed for renal function deterioration studies in patients with MM or MG following administration of iodine-based contrast media. Data collection and analysis were performed according to the PRISMA statement 2009. Eligibility criteria and methods of analysis were specified in advance. Cohort and case-control studies reporting changes in renal function were included. RESULTS: Thirteen studies were selected that reported 824 iodine-based contrast medium administrations in 642 patients with MM or MG, in which 12 unconfounded cases of PC-AKI were found (1.6 %). The majority of patients had intravenous urography with high osmolality ionic contrast media after preparatory dehydration and purgation. CONCLUSIONS: MM and MG alone are not risk factors for PC-AKI. However, the risk of PC-AKI may become significant in dehydrated patients with impaired renal function. Hypercalcaemia may increase the risk of kidney damage, and should be corrected before contrast medium administration. Assessment for Bence-Jones proteinuria is not necessary. KEY POINTS: • Monoclonal gammopathies including multiple myeloma are a large spectrum of disorders. • In monoclonal gammopathy with normal renal function, PC-AKI risk is not increased. • Renal function is often reduced in myeloma, increasing the risk of PC-AKI. • Correction of hypercalcaemia is necessary in myeloma before iodine-based contrast medium administration. • Bence-Jones proteinuria assessment in myeloma is unnecessary before iodine-based contrast medium administration.
format Online
Article
Text
id pubmed-5740198
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-57401982018-01-01 Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines Stacul, Fulvio Bertolotto, Michele Thomsen, Henrik S. Pozzato, Gabriele Ugolini, Donatella Bellin, Marie-France Bongartz, Georg Clement, Olivier Heinz-Peer, Gertraud van der Molen, Aart Reimer, Peter Webb, Judith A. W. Eur Radiol Contrast Media OBJECTIVES: Many radiologists and clinicians still consider multiple myeloma (MM) and monoclonal gammopathies (MG) a contraindication for using iodine-based contrast media. The ESUR Contrast Media Safety Committee performed a systematic review of the incidence of post-contrast acute kidney injury (PC-AKI) in these patients. METHODS: A systematic search in Medline and Scopus databases was performed for renal function deterioration studies in patients with MM or MG following administration of iodine-based contrast media. Data collection and analysis were performed according to the PRISMA statement 2009. Eligibility criteria and methods of analysis were specified in advance. Cohort and case-control studies reporting changes in renal function were included. RESULTS: Thirteen studies were selected that reported 824 iodine-based contrast medium administrations in 642 patients with MM or MG, in which 12 unconfounded cases of PC-AKI were found (1.6 %). The majority of patients had intravenous urography with high osmolality ionic contrast media after preparatory dehydration and purgation. CONCLUSIONS: MM and MG alone are not risk factors for PC-AKI. However, the risk of PC-AKI may become significant in dehydrated patients with impaired renal function. Hypercalcaemia may increase the risk of kidney damage, and should be corrected before contrast medium administration. Assessment for Bence-Jones proteinuria is not necessary. KEY POINTS: • Monoclonal gammopathies including multiple myeloma are a large spectrum of disorders. • In monoclonal gammopathy with normal renal function, PC-AKI risk is not increased. • Renal function is often reduced in myeloma, increasing the risk of PC-AKI. • Correction of hypercalcaemia is necessary in myeloma before iodine-based contrast medium administration. • Bence-Jones proteinuria assessment in myeloma is unnecessary before iodine-based contrast medium administration. Springer Berlin Heidelberg 2017-08-30 2018 /pmc/articles/PMC5740198/ /pubmed/28856420 http://dx.doi.org/10.1007/s00330-017-5023-5 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Contrast Media
Stacul, Fulvio
Bertolotto, Michele
Thomsen, Henrik S.
Pozzato, Gabriele
Ugolini, Donatella
Bellin, Marie-France
Bongartz, Georg
Clement, Olivier
Heinz-Peer, Gertraud
van der Molen, Aart
Reimer, Peter
Webb, Judith A. W.
Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines
title Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines
title_full Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines
title_fullStr Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines
title_full_unstemmed Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines
title_short Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines
title_sort iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and esur contrast media safety committee guidelines
topic Contrast Media
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740198/
https://www.ncbi.nlm.nih.gov/pubmed/28856420
http://dx.doi.org/10.1007/s00330-017-5023-5
work_keys_str_mv AT staculfulvio iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT bertolottomichele iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT thomsenhenriks iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT pozzatogabriele iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT ugolinidonatella iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT bellinmariefrance iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT bongartzgeorg iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT clementolivier iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT heinzpeergertraud iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT vandermolenaart iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT reimerpeter iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT webbjudithaw iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines
AT iodinebasedcontrastmediamultiplemyelomaandmonoclonalgammopathiesliteraturereviewandesurcontrastmediasafetycommitteeguidelines